DOW JONES NEWSWIRES -- Human Genome Sciences Inc. (HGSI) said a medical-journal article published Friday gives a positive review to the primary endpoints the company is using to test its lupus drug Benlysta. The announcement may heighten speculation that GlaxoSmithKline PLC (GSK), Human Genome’s partner in developing the drug, could be interested in buying out the company.
